Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
74 Results Found
Fact Sheet: The 340B Drug Pricing Program
Learn what the HHS 340B Drug Pricing Program is and what 340B hospitals are. The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients by providing 340B drug pricing discounts and expand health services to the patients and communities they serve.
Resources to Address 340B Underpayments by Medicare Advantage Organizations
To assist members in their efforts to obtain reimbursement under their contracts with their MAO plans, we have identified and spoken with four outside law firms that have considerable experience with 340B questions and litigating against insurers on issues like these.
HHS Issues Final Remedy for Its Unlawful 340B Payment Cuts from 2018 to 2022
Following last year’s unanimous Supreme Court decision in favor of the AHA and others, the Department of Health and Human Services Nov. 2 issued a final rule outlining the agency’s remedy for the unlawful payment cuts to certain hospitals that participate in the 340B Drug Pricing Program.
Judge Rules that HHS Must Immediately Halt Unlawful Reimbursement Cuts to Certain 340B Hospitals for Rest of 2022
The United States District Court for the District of Columbia today ruled in favor of the AHA, holding that the Department of Health and Human Services must immediately halt the departments’ unlawful cuts to outpatient reimbursement rates for the remainder of 2022 for certain hospitals that participate in the 340B Drug Pricing Program.
Amicus Brief: AHA, Hospital Groups Urge Appeals Courts to Uphold 340B Requirements Re: Novartis-United Therapeutics Corp. v. Johnson
The AHA, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, and Children’s Hospital Association yesterday urged the U.S. Courts of Appeals for the 3rd and District of Columbia Circuits to require drug companies to fulfill their legal obligations to provide 340B discounted drugs to eligible hospitals and health systems, regardless of whether the drugs are dispensed on site or through contract pharmacies.
Judge Orders HHS to Immediately Halt Unlawful Reimbursement Cuts for Remainder of 2022
Judge orders HHS to immediately halt unlawful reimbursement cuts for remainder of 2022 re: 340B.
AHA's Reply in Support of Plaintiffs’ Motion to Vacate the Unlawful Portion of the 2022 OPPS Rule Re: 340B
AHA files reply brief as district court considers 340B payment remedy for the remainder of 2022.
In OPPS final rule, CMS phases in clinic visit cuts, expands 340B reductions
The Centers for Medicare & Medicaid Services today issued its calendar year 2019 outpatient prospective payment and ambulatory surgical center final rule, which updates hospital OPPS rates by 1.35 percent in CY 2019 compared to CY 2018.
Supreme Court Rules Unanimously in Favor of AHA, Others in 340B Case
The Supreme Court of the United States today
Blog: Key Insights from Today’s Supreme Court Oral Arguments in AHA’s 340B Case
With a few hours to digest this morning’s oral argument in American Hospital Association v. Becerra, I wanted provide a few high-level reactions.